A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab in Combination With Ipilimumab in Advanced Solid Tumors

Trial Profile

A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab in Combination With Ipilimumab in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2017

At a glance

  • Drugs Entinostat (Primary) ; Nivolumab (Primary) ; Ipilimumab
  • Indications Adenocarcinoma; Breast cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
    • 03 Dec 2015 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top